Patents Assigned to The Rockefeller University
  • Patent number: 11325966
    Abstract: This invention relates to broadly neutralizing and potent anti-HIV-1 antibodies, kits, and methods of use thereof.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: May 10, 2022
    Assignees: The Rockefeller University, California Institute of Technology
    Inventors: Michel Nussenzweig, Natalia T. Freund, Pamela J. Bjorkman, Louise Scharf
  • Patent number: 11325920
    Abstract: The present disclosure includes novel compounds useful as antimicrobial agents. The present disclosure further includes methods useful. The present disclosure further includes compositions and methods for treating or preventing a bacterial infection. The present disclosure further includes compositions and methods useful for preventing or reducing the growth or proliferation of microorganisms.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: May 10, 2022
    Assignee: The Rockefeller University
    Inventors: Sean Brady, James Peek
  • Publication number: 20220135985
    Abstract: The invention provides for systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for selecting specific cells by introducing precise mutations utilizing the CRISPR/Cas system.
    Type: Application
    Filed: October 18, 2021
    Publication date: May 5, 2022
    Applicants: The Broad Institute, Inc., Massachusetts Institute of Technology, The Rockefeller University
    Inventors: Feng Zhang, David Benjamin Turitz Cox, Luciano Marraffini, David Olivier Bikard, Wenyan Jiang, Neville Espi Sanjana
  • Patent number: 11312723
    Abstract: Pyranoyrazoles and pyrazolopyridines of formula I or formula II are disclosed: These compounds inhibit Coagulation Factor XIIa in the presence of thrombin and other coagulation factors. They are useful to treat autoimmune diseases.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: April 26, 2022
    Assignee: THE ROCKEFELLER UNIVERSITY
    Inventors: Manish P. Ponda, Harold Selnick, Melissa Egbertson, Jan L. Breslow
  • Publication number: 20220120686
    Abstract: A multi-photon imaging system includes a laser module having a first channel for outputting a two-photon excitation laser pulse and a second channel for outputting a three-photon excitation laser pulse. The system further includes a first optical path for guiding the two-photon laser pulse from the first channel of the laser module and a second optical path for guiding the three-photon laser pulse from the second channel of the laser module. A microscope is also provided for simultaneously receiving the two-photon laser pulse from the first optical path and the three-photon laser pulse from the second optical path, and simultaneously, or with well controllable delays, delivering the two-photon laser pulse and the three-photon pulse to a target volume. The system further includes a photodetector configured to collect photons generated within the target volume in response to simultaneous excitation of the target volume by both the two-photon laser pulse and the three-photon laser pulse.
    Type: Application
    Filed: January 30, 2020
    Publication date: April 21, 2022
    Applicant: The Rockefeller University
    Inventors: Alipasha VAZIRI, Siegfried WEISENBURGER
  • Patent number: 11299732
    Abstract: Provided are compositions and methods for cleaving a DNA sequence in a cell. The methods involve comprising introducing into a cell a recombinant vector containing a clustered regularly interspaced short palindromic repeats (CRISPR) system. The system includes a CRISPR RNA (crRNA) targeted to a DNA sequence in the cell that is operatively linked to a promoter; and CRISPR-associated enzymes (Cas) 10, Cas6, and at least one Csm protein. The Cas 10 cleaves the DNA sequence only during transcription of the DNA sequence that is operatively linked to the promoter. Also provided are recombinant vectors for modifying cells, cells that contain the recombinant vectors and modifications introduced by them, and kits that include the modified vectors.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: April 12, 2022
    Assignee: The Rockefeller University
    Inventors: Luciano Marraffini, Gregory Goldberg, Poulami Samai
  • Publication number: 20220095998
    Abstract: Hyperspectral dermoscopy images obtained in N wavelengths in the 350 nm to 950 nm range with a hyperspectral imaging camera are processed to obtain imaging biomarkers having a spectral dependence. Machine learning is applied to the imaging biomarkers to generate a diagnostic classification.
    Type: Application
    Filed: July 7, 2021
    Publication date: March 31, 2022
    Applicant: THE ROCKEFELLER UNIVERSITY
    Inventor: Daniel Gareau
  • Publication number: 20220054449
    Abstract: A treatment for inflammatory dermatoses, such as psoriasis and atopic dermatitis (eczema), is disclosed that utilizes topical administration of a halogenated xanthene, such as rose bengal, together with administration of one or more complementary targeted systemic dermatology therapies, preferably a therapy that addresses the inflammatory pathway and is other than an NSAID that is a COX-1 and/or COX-2 inhibitor. Examples of complementary targeted systemic therapeutic ingredients include: corticosteroids, including betamethasone dipropionate and fluocinonide; dithranol; vitamin D analogs, including calcipotriol; and retinoids, non-biologics including methotrexate, ciclosporin, hydroxycarbamide, and fumarates including dimethyl fumarate; as well as one or more biologics, including antibodies or paratope-containing antibody portions to TNF-?, antibodies to pro-inflammatory cytokines interleukin-12, interleukin-23 and interleukin-17, and TNF inhibitors.
    Type: Application
    Filed: September 3, 2021
    Publication date: February 24, 2022
    Applicants: The Rockefeller University, Provectus Pharmatech, Inc.
    Inventors: James G. Krueger, Sandra Garcet, Jamie Singer, Eric A. Wachter
  • Patent number: 11225524
    Abstract: The present disclosure provides antibodies that specifically bind to Mer Tyrosine Kinase (MERTK) (e.g., human MERTK, or both human and mouse MERTK) and compositions comprising such antibodies, wherein said antibody agonizes MERTK signaling on endothelial cells. The present disclosure also provides methods for treating cancer, by administering an antibody that specifically binds to MERTK and agonizes MERTK signaling on endothelial cells.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: January 18, 2022
    Assignee: The Rockefeller University
    Inventors: Sohail Tavazoie, Nils Halberg, Masoud Tavazoie
  • Publication number: 20220002391
    Abstract: The present invention relates to broadly neutralizing anti-HIV-1 antibodies and isolated antigens. Also disclosed are related methods and compositions.
    Type: Application
    Filed: September 10, 2021
    Publication date: January 6, 2022
    Applicants: The Rockefeller University, California Institute of Technology
    Inventors: Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf, Johannes Scheid
  • Publication number: 20220002390
    Abstract: The present invention relates to anti-HIV antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.
    Type: Application
    Filed: September 9, 2021
    Publication date: January 6, 2022
    Applicants: The Rockefeller University, California Institute of Technology
    Inventors: Hugo Mouquet, Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf
  • Patent number: 11203739
    Abstract: Disclosed herein are compositions, systems, and methods for modulating proliferation, differentiation and pluripotency of cells.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: December 21, 2021
    Assignees: Memorial Sloan-Kettering Cancer Center, The Rockefeller University
    Inventors: Lydia W. S. Finley, Bryce W. Carey, Craig B. Thompson, C. David Allis
  • Patent number: 11199691
    Abstract: An imaging signal extraction apparatus comprising: an interface; a processing device, the processing device operatively coupled to the interface; and a computer readable medium comprising instructions that, when executed by the processing device, perform operations comprising: a) generating a two-dimensional image from imaging information obtained from the interface, thereby estimating ballistic component of the imaging information; b) generating a three-dimensional image by remapping the two-dimensional image; c) identifying a candidate object in the three-dimensional image; d) obtaining an estimated spatial forward model of the candidate object by mapping the three-dimensional image of the candidate object with a point-spread-function associated with the imaging apparatus; e) obtaining background-corrected data by using the estimated spatial forward model of the candidate object and estimated temporal components; and f) iteratively updating the estimated spatial forward model and estimated temporal componen
    Type: Grant
    Filed: October 7, 2020
    Date of Patent: December 14, 2021
    Assignee: The Rockefeller University
    Inventors: Alipasha Vaziri, Tobias Noebauer, Oliver Skocek
  • Patent number: 11192889
    Abstract: Tetrahydronaphthyridines of formula are disclosed. These compounds selectively inhibit ?V?3 without activating the ?V?3 receptor. They are useful for treating osteoporosis, acute myelogenous leukemia, sickle cell disease, focal segmental glomerulosclerosis, fibrosis, supravalvular aortic stenosis associated with Williams syndrome, tumors expressing ?V?3, tumor metastasis, bone resorption, T-cell lymphoma, retinal disease, age-related macular degeneration, diabetic retinitis, and herpes simplex virus infection. They may also be used for inhibiting tumor angiogenesis.
    Type: Grant
    Filed: July 5, 2017
    Date of Patent: December 7, 2021
    Assignee: THE ROCKEFELLER UNIVERSITY
    Inventors: Barry S. Coller, Marta Filizola, Michael Andrew Foley
  • Patent number: 11192893
    Abstract: Compounds of formula: are useful as antitumor agents. In these compounds, R10 is (a) (C1-C10) hydrocarbyl, (C1-C10)halohydrocarbyl, (C1-C6)hydroxyalkyl, or or R10 is (b) in which Q and A are linkers and Ar is optionally substituted monocyclic or bicyclic aryl or heteroaryl.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: December 7, 2021
    Assignee: The Rockefeller University
    Inventors: Tarun M. Kapoor, Moriteru Asano, Kazuyoshi Aso, Michael A. Foley, Yoshiyuki Fukase, Hideki Furukawa, Yashuhiro Hirata, Sachie Takashima, Tomohiro Okawa, Yuta Tanaka, Yayoi Yoshitomi
  • Patent number: 11180744
    Abstract: Acinetobacter lysin polypeptides and variants peptides with killing activity against gram negative bacteria. Methods for treating bacterial infections or bacterial colonization using Acintobacter lysin polypeptides.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: November 23, 2021
    Assignee: The Rockefeller University
    Inventors: Vincent Fischetti, Raymond Schuch, Rolf Lood, Benjamin Winer
  • Publication number: 20210332110
    Abstract: This disclosure provides novel broadly neutralizing anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof. The disclosed anti-SARS-CoV-2 antibodies constitute a novel therapeutic strategy in protection from SARS-CoV-2 infections.
    Type: Application
    Filed: April 28, 2021
    Publication date: October 28, 2021
    Applicant: The Rockefeller University
    Inventors: Michel Nussenzweig, Davide F. Robbiani
  • Patent number: 11155799
    Abstract: The present invention provides methods, compositions and articles of manufacture useful for the prophylactic and therapeutic amelioration and treatment of gram-positive bacteria, including Streptococcus and Staphylococcus, and related conditions. The invention provides compositions and methods incorporating and utilizing Streptococcus suis derived bacteriophage lysins, particularly PlySs2 and/or PlySs1 lytic enzymes and variants thereof, including truncations thereof. Methods for treatment of humans are provided.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: October 26, 2021
    Assignee: THE ROCKEFELLER UNIVERSITY
    Inventors: Vincent A. Fischetti, Jonathan Schmitz, Daniel Gilmer, Chad Euler
  • Patent number: 11155605
    Abstract: The present invention relates to broadly neutralizing anti-HIV-1 antibodies and isolated antigens. Also disclosed are related methods and compositions.
    Type: Grant
    Filed: September 23, 2019
    Date of Patent: October 26, 2021
    Assignees: THE ROCKEFELLER UNIVERSITY, CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf, Johannes Scheid
  • Patent number: 11149081
    Abstract: Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) broadly neutralizing antibodies having improved potency and breadth for neutralizing a range of HIV strains. Combinations of broadly neutralizing antibodies can also improve potency over a single antibody composition.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: October 19, 2021
    Assignees: THE ROCKEFELLER UNIVERSITY, CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Ron Diskin, Anthony P. West, Michel C. Nussenzweig, Pamela J. Bjorkman